![]() ![]() Marx, Ph.D., President and COO, Cerapedics. From sports medicine to spine, from cardiac and vascular to skin and wound, from craniomaxillofacial to general orthopedics and trauma, our comprehensive. “The next generation product we’re developing with DSM is showing tremendous potential, and will allow us to bring the bone forming potential of the P-15 technology into the lumbar spine,” said Jeffrey G. following the FDA Premarket Approval (PMA) of i-FACTOR Bone Graft, and we are excited to be partnered with DSM in delivering our next generation product to market,” said Glen Kashuba, CEO, Cerapedics. “Over the past year we have been focused on accelerating our commercialization efforts in the U.S. This website contains information which is targeted to a wide range of audiences and could contain product details or information otherwise not. The availability of the products is subject to compliance with the regulatory requirements of each market. Cerapedics is partnering with DSM to collaboratively develop and commercialize the next generation of this technology. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. for anterior cervical discectomy and fusion (ACDF) procedures since late 2015. The company’s first-generation product, i-FACTOR™ Peptide Enhanced Bone Graft, has been commercially available outside of the U.S. “Together, from concept to commercialization, we are at the leading edge of advanced healing solutions.”Ĭerapedics developed P-15 technology to support bone growth through cell attraction, attachment, and activation. S deficiency (type I) Factor V Leiden Prothrombin G20210A Dysfibrinogenemia. This ensures that our staff are continuously challenged, and re-skilled. Acquired Inherited Mixed Older age Major surgery and orthopedic surgery Low. As part of our skills development process we constantly research, analyze and explore new (and current) technologies. “The partnership combines the industry leading expertise and capabilities in bioceramic materials of DSM with Cerapedics’ innovative growth factor, delivering a new product solution to improve people’s lives,” said David Yonce, Vice President and Global Head of Innovation at DSM Biomedical. iFactor provides the Financial Industry with highest quality highly skilled developers. Philippe Lauweryns, orthopedic surgeon at Sint-Trudo Ziekenhuis hospital in Belgium, concluded i-FACTOR biologic bone graft may be a viable alternative to autograft in. ![]() #Ifactor ortho full#Under the partnership agreement with Cerapedics, DSM will also provide a collagen carrier, final packaging, and full support from concept through commercialization. The strategic partnership aligns DSM’s regenerative materials capabilities with proprietary synthetic small peptide (P-15) technology developed by Cerapedics.ĭSM’s newest bioceramic platform is a carbonated apatite matrix designed for fast, predictable remodeling in bone graft substitute applications. DSM Biomedical, a global solutions provider in biomedical science and regenerative medicine, today announced that it is partnering with Cerapedics, a privately-held orthobiologics company, to develop and manufacture the next generation peptide enhanced bone graft. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |